Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice

PloS One
Susan P FoyStefanie J Mandl

Abstract

Poxvirus-based active immunotherapies mediate anti-tumor efficacy by triggering broad and durable Th1 dominated T cell responses against the tumor. While monotherapy significantly delays tumor growth, it often does not lead to complete tumor regression. It was hypothesized that the induced robust infiltration of IFNγ-producing T cells into the tumor could provoke an adaptive immune evasive response by the tumor through the upregulation of PD-L1 expression. In therapeutic CT26-HER-2 tumor models, MVA-BN-HER2 poxvirus immunotherapy resulted in significant tumor growth delay accompanied by a robust, tumor-infiltrating T cell response that was characterized by low to mid-levels of PD-1 expression on T cells. As hypothesized, this response was countered by significantly increased PD-L1 expression on the tumor and, unexpectedly, also on infiltrating T cells. Synergistic benefit of anti-tumor therapy was observed when MVA-BN-HER2 immunotherapy was combined with PD-1 immune checkpoint blockade. Interestingly, PD-1 blockade stimulated a second immune checkpoint molecule, LAG-3, to be expressed on T cells. Combining MVA-BN-HER2 immunotherapy with dual PD-1 plus LAG-3 blockade resulted in comprehensive tumor regression in all mice treated...Continue Reading

References

May 1, 1990·The Journal of Experimental Medicine·F TriebelT Hercend
Sep 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·U MoebiusE L Reinherz
Jul 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Valéry RenardDana R Leach
Apr 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Creg J WorkmanDario A A Vignali
Mar 25, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chie Kudo-SaitoJames W Hodge
Jun 23, 2005·European Journal of Immunology·Malgorzata KisielowKlaus Karjalainen
Oct 13, 2007·The Journal of Clinical Investigation·Joseph F GrossoCharles G Drake
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Sep 24, 2008·Proceedings of the National Academy of Sciences of the United States of America·Shawn D BlackburnE John Wherry
Feb 10, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Creg J WorkmanDario A A Vignali
May 21, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Joseph F GrossoCharles G Drake
Jun 25, 2009·Expert Opinion on Investigational Drugs·Ravi A MadanJames L Gulley
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip W KantoffWayne R Godfrey
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
May 19, 2012·Seminars in Oncology·Ravi A MadanJames L Gulley
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Aug 30, 2013·Science Translational Medicine·Stefani SprangerThomas F Gajewski
Nov 6, 2013·Annual Review of Medicine·David B PageJedd D Wolchok
Feb 12, 2014·Cancer Immunology, Immunotherapy : CII·Caroline JochemsJeffrey Schlom
Mar 22, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kurt A SchalperDavid L Rimm
Apr 30, 2014·Cancer Immunology Research·James L GulleyJeffrey Schlom
Oct 21, 2014·Journal for Immunotherapy of Cancer·Stefanie J MandlAlex Franzusoff
Jun 7, 2015·Current Opinion in Pharmacology·Joel Sunshine, Janis M Taube

❮ Previous
Next ❯

Citations

Mar 5, 2017·Immunological Reviews·Lawrence P AndrewsDario A A Vignali
Aug 8, 2017·Current Medicinal Chemistry·Bin LiPingping Chen
May 26, 2017·Oncotarget·Federica CappucciniIrina Redchenko
Oct 16, 2019·Nature Immunology·Lawrence P AndrewsDario A A Vignali
Jan 18, 2019·PLoS Pathogens·Colin G GraydonKeith R Fowke
Nov 12, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tuba N GideGeorgina V Long
May 1, 2021·International Journal of Molecular Sciences·Mankgopo M KgatleMike M Sathekge

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
Fluorescence

Software Mentioned

ImageJ
PROSTVAC
GraphPad Prism
FlowJo
CompuSyn
GraphPad

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.